Immunofocusing design of a fusion glycoprotein monomer vaccine for respiratory syncytial virus
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.07.040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Qianqian Li und 21 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China; State Key Laboratory of Re…. Hauptthemen laut MEDLINE: Viral Fusion Proteins, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) can cause severe lower respiratory tract infections in infants and the elderly. Previously, most RSV vaccine antigen design strategies have focused on the stability of the prefusion (PreF) protein trimer conformation. We hypothesized that the RSV monomer might serve as a vaccine candidate immunogen. Here, we constructed an immunofocusing-based RSV F protein Q74 truncated monomer by truncating the RSV F protein and retaining only the head and neck regions. The structural prediction and protein antigenicity characterization of Q74 truncated monomer both indicated that it could bind to the antigenic site Ø-specific antibody D25, suggesting that this immunogen retained the structural features of PreF. In addition, the Q74 truncated monomer not only induced neutralizing and binding antibodies with a strength comparable to that of DS-Cav1 but also focused the immune response on antigenic site Ø and site II. In summary, we found that the RSV F protein monomer designed based on immunofocusing could induce relative immunogenicity and immune protection, providing a design strategy for RSV vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China; State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Medical Biology, Chi…
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China.
Förderung
- Chinese Academy of Medical Sciences
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica
Zitieren
APA
Li, Q., Li, Z., Chen, J., He, Q., Xiao, H., Li, H., Li, H., Zhang, H., Yang, Y., Bi, R., Li, Z., Xiao, S., Bi, Y., Liang, B., Huang, L., Zhang, M., Tong, J., Long, H., Li, R., …, & Wang, Y. (2025). Immunofocusing design of a fusion glycoprotein monomer vaccine for respiratory syncytial virus. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.07.040
Vancouver
Li Q, Li Z, Chen J, He Q, Xiao H, Li H, et al. Immunofocusing design of a fusion glycoprotein monomer vaccine for respiratory syncytial virus. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.07.040
BibTeX
@article{Li2025,
author = {Li, Qianqian and Li, Zhiming and Chen, Jiamin and He, Qiuju and Xiao, Hongjian and Li, Haiwei and Li, Huan and Zhang, Heng and Yang, Yaoyun and Bi, Rong and Li, Zichen and Xiao, Song and Bi, Yanwei and Liang, Bingyan and Huang, Luxia and Zhang, Mengyi and Tong, Jincheng and Long, Haoyue and Li, Ru and Duan, Jinmei and Li, Zhihua and Wang, Youchun},
title = {Immunofocusing design of a fusion glycoprotein monomer vaccine for respiratory syncytial virus},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.07.040}
}
EUVIMED